Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

ific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
(Date:10/20/2014)... OncLive® is pleased ... at Thomas Jefferson University has joined its Strategic ... Alliance Partnership program, the Sidney Kimmel Cancer Center ... awareness of the Center’s cutting-edge research programs, comprehensive ... and other health care professionals from the Sidney ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... from Product Sales Increased 149% to $3.5 Million - ... - Gross Profit ... AMDL, Inc. (Amex: ADL ),is a vertically integrated ... Jiangxi and Jilin,China. Through its wholly owned subsidiary Jade Pharmaceutical ...
... scatter and channel light, University of California, San ... junction solar cells with the potential for nearly ... Diego effort to break the theoretical limit of ... recently received a big funding boost from the ...
... 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), a leading ... financial and operational results for the first quarter ended,March ... Company, is,developing dirucotide (also known as MBP8298), a synthetic ... in Canada, Europe and the US., "During the ...
Cached Biology Technology:AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 2AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million 3UC San Diego nanostructures will raise thin-film solar cell efficiency 2BioMS Medical announces first quarter 2008 results 2BioMS Medical announces first quarter 2008 results 3BioMS Medical announces first quarter 2008 results 4BioMS Medical announces first quarter 2008 results 5
(Date:10/16/2014)... can be cultivated efficiently, they are anything but ... by monoculture cultivation is becoming increasingly evident. Despite ... form and are regarded as the sole possibility ... quite wrongfully, finds Bernhard Schmid, an ecology professor ... novel form of agriculture and forestry. After all, ...
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... PA, January 15, 2013 A new study has ... counteract some pathologic features in a mouse model of ... known to produce long-term improvement of the symptoms in ... characterized by progressive muscle wasting, respiratory and cardiac impairments, ...
... should sharpen their ability to spot environmental conditions that ... having a certain abundance of fish assures how much ... harvest of fish is only closely linked to abundance ... a University of Washington-led study, according to Ray Hilborn, ...
... A research team involving several scientists from the University ... in the devastating pine beetle outbreaks ravaging the West: ... streams as scientists had previously believed. According to ... shows that smaller trees and other vegetation that survive ...
Cached Biology News:Tamoxifen ameliorates symptoms of Duchenne muscular dystrophy 2Potential harvest of most fish stocks largely unrelated to abundance 2Potential harvest of most fish stocks largely unrelated to abundance 3CU-led study shows pine beetle outbreak buffers watersheds from nitrate pollution 2CU-led study shows pine beetle outbreak buffers watersheds from nitrate pollution 3
Request Info...
Request Info...
... Art GLP facility with capabilities from ... fermentation. Coordinated process development from ... operation capable of simultaneous production runs ... Hosts include: Bacteria, Yeast, Fungi, ...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
Biology Products: